AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 212 min read$ABT

Abbott (ABT) Q3 2026 Earnings Call Transcript

Abbott (ABT) reported Q3 2026 earnings, announcing plans to spin off its nutrition business into a separate, publicly traded company. The move follows a strategic review, aiming to enhance value and focus for both entities. Abbott's Q3 sales grew 7%, with diagnostics up 6.5% and nutrition up 5%. The new nutrition company will have $8.5B in annual sales and is expected to join the S&P 500. Daniel Salvadori will lead the new company, with Abbott retaining a diversified healthcare portfolio.

Original reporting
finance.yahoo.com
Published Oct 21, 2026, 6:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 6:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Abbott (ABT) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ABTNeutralMed
01

Why it matters

The spin‑off is expected to create a focused nutrition company with ~$8.5 bn sales, likely qualifying for S&P 500 inclusion, while Abbott retains higher‑growth, higher‑margin segments.

02

Market read

The announcement reshapes Abbott's portfolio and introduces a new public nutrition player, influencing both healthcare and consumer‑goods investors.

03

What to watch

Execution risk of the separation, tax implications, and timing of the new company's IPO could affect valuation.

Relevance 7/10Novelty 8/10Timing: today, during the earnings call

Background

Abbott's Q3 2026 earnings call covered strong growth across its core businesses and introduced a strategic split of its nutrition segment.

Company-level read

Ticker impact

$ABTNeutralHigh confidence
Context

Abbott announced during its Q3 2026 earnings call that it will separate its nutrition business into an independent, publicly traded company.

Expected impact

potential upside for ABT as investors price in a cleaner portfolio and upside for the future nutrition spin‑off.

Evidence & confidence

The announcement is a primary, material corporate action with significant scale; market participants will reassess valuation.

Market effects

Sector

Nutrition and health‑care consumer products sector may see increased M&A interest and valuation re‑rating.

Regional

U.S. healthcare and consumer‑goods markets could experience modest reallocation of capital.

Global

Creates a new globally listed pure‑play nutrition company, potentially affecting global consumer‑health indices.

Counterpoint

What could challenge this read

The spin‑off could distract management and dilute Abbott's scale, leading to short‑term pressure on ABT.

Key entities

  • company
    Abbott Laboratories

    US‑listed healthcare conglomerate (ticker ABT) announcing the spin‑off.

  • person
    Daniel Salvadori

    Appointed CEO of the future independent nutrition company.

Read at source← All news

StoryAbbott to spin off Nutrition business into independent public company by 2027

Also covered by

4 outlets

Related articles

OCT 21
$ABTMed

Abbott Laboratories (ABT) Plans Nutrition Spin-Off to Sharpen Fo

Abbott Laboratories (ABT) plans to spin off its Nutrition division, which generates $8.5B in annual sales, to focus on higher-growth segments like medical devices and diagnostics. The company offers a 2.69% dividend yield with a 80% payout ratio and a GF Value of $135.69, suggesting modest undervaluation. ABT's GF Score is 82/100, reflecting strong financial health. Insiders have sold more shares than bought in the past year, while 23 gurus hold positions, with mixed recent activity.

gurufocus.com2 min
OCT 21
$ABTHighAI 8/10

Abbott options flow points to downside caution after guidance cut

Abbott Laboratories (ABT) shares fell 3.56% to $98.80 after Q3 results met EPS estimates and slightly beat revenue forecasts, but full-year sales growth guidance was lowered to 6%. Options flow showed a defensive tilt with 58% puts, including a diagonal put spread of 2,224 contracts. Implied volatility and downside put costs decreased, suggesting the market has priced in the earnings reset.

investing.com2 min
OCT 21
$RTXHighAI 8/10

Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm

Nasdaq Composite and Russell 2000 led a three-day market rally, with Nasdaq up 2.14% and Russell 2000 up 2.36% for the week. The Dow and S&P 500 also gained over 1.2%. Several companies reported earnings, including RTX (NYSE: RTX), Abbott (NYSE: ABT), CME Group (Nasdaq: CME), M/I Homes (NYSE: MHO), and Lockheed Martin (NYSE: LMT). RTX reported $25.0B in Q3 sales and raised its full-year outlook. Abbott posted 14.5% sales growth. CME Group saw record Q3 revenue.

prnewswire.com3 min
OCT 21
$ABTHighAI 8/10

Abbott Laboratories (ABT) Reports Q3 Results and Plans Nutrition

Abbott Laboratories (ABT) reported Q3 adjusted EPS of $1.42, with revenue up 14.5% YoY to $13.01B. Q4 EPS guidance met expectations, but full-year 2026 sales growth forecast was lowered to ~6%. The company plans to spin off its Nutrition business by the end of 2027, aiming to focus on higher-growth healthcare sectors. Medical Devices and Diagnostics saw strong growth, while Diabetes Care faced reimbursement challenges.

gurufocus.com2 min
OCT 21
$ABTMedAI 8/10

What Abbott Laboratories (ABT) Said on Its Q3 Earnings Call

Abbott Laboratories (ABT) reported Q3 comparable sales up 7% and adjusted EPS of $1.42, in line with guidance. The company expects sales growth to accelerate post-nutrition separation and forecasts Q4 adjusted EPS of $1.62-$1.67. Abbott also provided updates on its medical device pipeline and near-term pressures in electrophysiology and diabetes care.

finance.yahoo.com3 min
OCT 21
$ABTMedAI 8/10

Abbott Laboratories Q3 2026 Earnings Call Summary

Abbott Laboratories reported Q3 2026 sales growth of 7%, driven by diagnostics and electrophysiology. The company plans to separate its nutrition business by late 2027, aiming for accelerated sales and margin growth. Q4 guidance includes a temporary headwind in the LAA market. Management expects continued growth in 2027, with new product launches. The nutrition spin-off is expected to be tax-free, with both entities maintaining strong capital positions.

finance.yahoo.com3 min